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Patients with primary immunoglobulin deficiency have lower immunoglobulin levels or
decreased immunoglobulin function, which makes these patients more susceptible
to bacterial infection. Most prevalent are the selective IgA deficiencies (∼1:3,000),
followed by common variable immune deficiency (∼1:25,000). Agammaglobulinemia
is less common (∼1:400,000) and is characterized by very low or no immunoglobulin
production resulting in a more severe disease phenotype. Therapy for patients with
agammaglobulinemia mainly relies on prophylactic antibiotics and the use of IgG
replacement therapy, which successfully reduces the frequency of invasive bacterial
infections. Currently used immunoglobulin preparations contain only IgG. As a result,
concurrent IgA and IgM deficiency persist in a large proportion of agammaglobulinemia
patients. Especially patients with IgM deficiency remain at risk for recurrent infections
at mucosal surfaces, which includes the respiratory tract. IgA and IgM have multiple
functions in the protection against bacterial infections at the mucosal surface. Because
of their multimeric structure, both IgA and IgM are able to agglutinate bacteria efficiently.
Agglutination allows for entrapment of bacteria in mucus that increases clearance from
the respiratory tract. IgA is also important for blocking bacterial adhesion by interfering
with bacterial adhesion receptors. IgM in its place is very well capable of activating
complement, therefore, it is thought to be important in complement-mediated protection
at the mucosal surface. The purpose of this Mini Review is to highlight the latest
advances regarding IgA- and IgM-enriched immunoglobulin replacement therapy. We
describe the different IgA- and IgM-enriched IgG formulations, their possible modes of
action and potential to protect against respiratory tract infections in patients with primary
immunoglobulin deficiencies.
Keywords: IgM, IgA, IgG, immunoglobulin replacement therapy, respiratory tract infections, primary
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ROLE FOR IMMUNOGLOBULIN
SUBCLASSES IN PROTECTION AGAINST
BACTERIAL INFECTIONS
Immunoglobulin production by B-lymphocytes is a sophisticated
adaptive immune defense mechanisms evolved in jawed
vertebrates (1). The absolute importance for immunoglobulins
in protection against infections is illustrated in patients that
completely lack immunoglobulin production, which is a lethal
condition due to increased susceptibility for invasive infection
(2). There are 5 main classes of immunoglobulins; IgG, IgM, IgA,
IgD and IgE, all having different properties and functions (3). For
this Mini Review, we will focus on IgG, IgM, and IgA and their
role in protection against bacterial respiratory tract infections.
Immunoglobulins are with 10–22 g/L a major serum
constituent. The majority of serum immunoglobulins are IgG
(∼75%), followed by IgA (∼15%) and IgM (∼10%) (4). IgG can
be subdivided into IgG1, IgG2, IgG3 and IgG4 and IgA can be
subdivided into IgA1 and IgA2. The half-life of immunoglobulins
vary, with 3 to 4 weeks for IgG1, IgG2 and IgG4, whereas this is
around 2 weeks for IgG3 (5, 6). Half-life for IgA and IgM is with
5 to 6 days much shorter compared to IgG (6, 7).
The different immunoglobulins have specific functions in
immunity. Upon binding to their targets, both IgG and IgM
are capable of activating complement through binding of C1q.
The ability to activate complement for IgG subclasses varies
due to differences in C1q binding, which is highest for IgG3,
followed by IgG1, IgG2 and is absent for IgG4 (8, 9). Recent
data indicate that IgG oligomerizes into hexamers, forming an
optimal configuration for C1q binding (10). This oligomerization
might explain the more efficient activation of complement by
IgM, (11–13) because it is present as polymeric structures (pIgM)
(14).
IgA is not able to activate complement directly. There are two
subclasses of IgA, IgA1 and IgA2, characterized by differences
in their hinge region (15). Whereas IgA1 is the predominant
subclass in serum, both IgA1 and IgA2 are present on the
mucosal surface (16). The majority of IgA at the mucosal
surface is dimeric (dIgA) (16), whereas the majority in serum is
monomeric (17). IgA ismost abundant at mucosal surfaces where
it has a role in protection against toxins, viruses and bacteria by
means of direct neutralization, or by preventing attachment to
the mucosal epithelium (18, 19).
IgA and IgM can be transported to mucosal surfaces
through the polymeric immunoglobulin receptor (pIgR) (20).
Only polymeric immunoglobulins containing a J-chain can be
transported by this receptor (21). The pIgR present on the
basolateral side of epithelial cells binds dIgA and pIgM, which
facilitates transcytosis to the apical side, where it is cleaved off
Abbreviations: Btk, Bruton tyrosine kinase; CVID, Common variable immune
deficiency; dIgA, Dimeric IgA; FcRN, Neonatal Fc receptor; FFP, Fresh frozen
plasma; IgGRT, IgG replacement therapy; IgRT, Immunoglobulin replacement
therapy=; IM-IgGRT, Intramuscular IgG replacement therapy; IV-IgGRT,
Intravenous IgG replacement therapy; PID, Primary immune deficiencies; pIgM,
Polymeric IgM; SC-IgGRT, Subcutaneously IgG replacement therapy; sIgA,
Secretory IgA; sIgAD, Selective IgA deficienciy; sIgM, Secretory IgM; sIgMD,
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and leaving the secretory components attached, resulting in the
formation of secretory IgA (sIgA) or sIgM (22, 23). Association of
the secretory component enhances resistance to proteolysis (24),
but does not affect the ability to activate complement (25).
IgG is not transported by the pIgR, but through the neonatal
Fc receptor (FcRn) (26). FcRn is able to transport IgG from the
basolateral to the apical side, and vice versa (27). This FcRn-
mediated retrograde transport and recycling of IgG is thought to
contribute to the prolonged half-life in serum (28, 29).
A successful strategy to protect healthy individuals from
respiratory tract infections is the use of vaccination. In the early
1990s, the Haemophilus influenzae serotype B (Hib) conjugate
vaccine entered the market, which decreased invasive Hib disease
cases substantially inmany countries (30–33). This Hib conjugate
vaccine is highly immunogenic and increases capsule-specific
antibody levels that not only protects against disease such as
pneumonia and meningitis, but also against nasopharyngeal
colonization (34). Hib vaccination elicits a combination of
serum immunoglobulin subclasses, mainly IgG, but also IgM
and IgA (35). Vaccination of children with the Streptococcus
pneumoniae polysaccharide conjugate vaccines (PCV) has shown
to increase capsule-specific IgG antibody levels (36) and
confer protection against nasopharyngeal colonization, otitis
media, pneumoniae and bacteremia (37–39). Vaccine-induced
polysaccharide capsule-specific antibodies initiate complement
deposition on the bacterial surface, which is essential for
opsonophagocytic killing of S. pneumoniae and H. influenzae in
whole blood (40).
IMMUNOGLOBULIN DEFICIENCIES
The diverse roles of the different immunoglobulin subclasses
in protection against infections is illustrated in patients with
primary immune deficiencies (PID), as described in more detail
below.
Selective IgA Deficiency
Selective IgA deficiency (sIgAD) is characterized by serum IgA
level of <7 mg/dL, with normal levels of both IgG and IgM
in individuals more than 4 years of age (41). Most patients are
clinically asymptomatic, but others show recurrent infections,
allergies and autoimmunity (2). Although rather prevalent, the
exact pathogenesis is unknown. Since sIgAD is heterogeneous
in presentation of disease symptoms, it is likely that different
aetiologies might be involved in the cause of this disease. There is
evidence for genetic predisposition based on familial clustering,
and mutations in many genes involved in cellular and humoral
immunity have been associated with sIgAD (42).
Recurrent respiratory tract infections are the most common
disease associated with sIgAD (43–45). When divided into
complete and partial IgA deficiency, a history of chronic or
recurrent infections is more often found in patients with
complete IgA deficiency (77%), compared to partial IgA
deficiency (20%) (44), suggesting that a lower IgA is associated
with frequent infections. Elevated levels of IgG or IgM are
found in a proportion of sIgAD patients (44–47), which might
compensate the IgA deficiency. Patients with sIgAD who had
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higher saliva IgM levels showed a lower infection incidence (47),
although this was not found in a later study (46). Patients with
sIgAD are usually not treated with IgG replacement therapy
(IgGRT), but it is recommended for individuals with IgA
deficiency and concomitant IgG2 subclass deficiency (48).
Selective IgM Deficiency
The European Society for Immunodeficiencies (ESID) Registry
defines selective IgM deficiency (sIgMD) as a serum IgM
concentration of 2 standard deviations below the normal level,
with normal levels of serum IgA and IgG, normal vaccination
responses and absence of T cell defects (41). The immunological
and clinical phenotype of sIgMD is very heterogeneous and
patients can remain asymptomatic (49). Similar to sIgAD,
patients with sIgMD often present with recurrent respiratory
problems (49, 50). In a cohort of 17 sIgMD patients, recurrent
upper respiratory tract infections were observed in 5 out of 6
patients with undetectable IgM levels (<0.05 g/L) (49). Although
for most sIgMD patients IgGRT was not required (49), it is
recommended for patients with recurrent or severe infections
(51).
Common Variable Immune Deficiencies
Patients with common variable immune deficiencies (CVID)
are characterized by a marked decrease of IgG or IgA with or
without low IgM levels, poor specific immunoglobulin responses
to vaccination and no profound T-cell deficiency (41). A
monogenic cause has been identified in 2–10% of CVID patients,
but most patients appear to be polygenic or multifactorial
disorders (52). Most CVID patients present with infectious
manifestations, commonly of the upper and lower respiratory
tract (53). The majority (70%) of CVID patients develop
chronic pulmonary complications including bronchiectasis and
bronchial wall thickening (54). To prevent especially respiratory
tract infections, IgGRT is the mainstay treatment for CVID
patients (55).
Agammaglobulinemia
Patients with agammaglobulinemia have very low or no serum
immunoglobulin levels, making these patients highly susceptible
to infections (2). The largest group of patients have X-linked
agammaglobulinemia (XLA), which is a caused by a defect in
the Btk gene encoding Bruton Tyrosine Kinsase (Btk), which
accounts for 85% of agammaglobulinemia patients. IgGRT is
recommended for all agammaglobulinemia patients to reduce
infections (56). Bacterial infections of the respiratory tract
are often seen in patients with agammaglobulinemia, prior to
diagnosis, but also after initiation of IgGRT (57–60), likely due
to the absence of IgA and IgM antibodies in IgGRT. As a results,
a large proportion of agammaglobulinemia patients develop
chronic lung diseases (57, 59).
PAST, PRESENT AND FUTURE OF
IMMUNOGLOBULIN REPLACEMENT
THERAPY
IgG for IgGRT is traditionally collected from the Cohn fraction
II after cold methanol precipitation (61, 62) and used to
prevent infections in patients with PID. Despite IgGRT, recurrent
infections, mainly of the respiratory tract, are reported (57–
60), and is associated with a lowered life-expectancy of CVID
and agammaglobulinemia patients (63, 64). Currently used
immunoglobulin preparations contain only IgG. As a result,
concurrent IgA and IgM deficiency persists in a large proportion
of immunoglobulin deficient patients, which results in recurrent
infections and development of chronic lung diseases such as
bronchiectasis (65, 66). Here, we summarize the current and
novel immunoglobulin replacement therapies possibly effective
in preventing bacterial respiratory tract infections.
In the Beginning; 1952
IgGRT was first introduced in 1952 by Colonel Ogden Bruton
and applied to the first patient with agammaglobulinemia (67).
This patient had an extensive history of infections, including
osteomyelitis, gastrointestinal infection, and multiple episodes of
epidemic parotitis, otitis media, pneumonia and sepsis for 4.5
years. After the third episode of epidemic parotitis, it was found
that the serum of this patient was deficient for immunoglobulins.
The patient was given subcutaneous IgGRT (SC-IgGRT) and
was free of invasive infections (67, 68). After this first success,
more individuals with agammaglobulinemia and other PID were
treated with IgGRT.Most patients received intramuscular IgGRT
(IM-IgGRT) (60) because uptake and bioavailability of IgG from
the muscle is better as compared to fatty tissue where it is
deposited by SC-IgGRT (69). However, injections were painful
and the volume that can be given is limited, therefore, alternative
administration methods were explored.
An advantage for SC-IgGRT is the ability for home treatment,
which was shown to be feasible and safe (70). Home treatment
is more convenient, and prevents loss of school or workdays
and hospital costs (70). Although SC-IgGRT was initially limited
by a slow infusion, this improved considerably over the past
years (71). Recently, a new SC-IgGRT formulation containing
recombinant hyaluronidase, which is an enzyme that cleaves the
extracellular matrix and increases tissue permeability. Therefore,
the use of recombinant hyaluronidase enables administration of
larger volumes of IgG and thereby decreases dosing frequency to
once in the 3–4 weeks, is in clinical trial (72).
Next Step, Intravenous IgG Replacement
Therapy
The largest disadvantage of both SC-IgGRT and IM-IgGRT is the
limited volume that can be administered per dose. As a result,
the patient requires frequent dosing, typically every week. With
intravenous IgGRT (IV-IgGRT), larger volumes can be giving,
which decreases the frequency of dosing to once in the 3–4
weeks. However, it requires venous access and the incidence of
systemic adverse reactions were high in the early years, mainly
due to vasomotor and cardiovascular manifestations, which was
most likely due to immunoglobulin aggregation and complement
activation (56, 73, 74). Later, modification of IV-IgGRT by
for instance ß-propiolactone, which prevents aggregation (75),
reduced the number of side-effects considerably (76) and soon
became the routine treatment regimen (77, 78). In a head-
to-head comparison, IV-IgGRT was given once every 4 weeks
and SC-IgGRT every week. Significant improvement in clinical
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parameters such as a lower number of days with acute respiratory
infections and IgG trough levels were found for IV-IgGRT (74).
This even improved further when IV-IgGRT was given once
every 3 weeks (74). Important for protection against respiratory
infections, serum opsonic capacity of H. influenzae and S.
pneumoniae increased when IV-IgGRT was administered once
every 3 weeks as compared to once every 4 weeks (74).
POSSIBLE IMPROVEMENTS; IgA- AND/OR
IgM-ENRICHED IMMUNOGLOBULIN
REPLACEMENT THERAPY
Nowadays, both SC-IgGRT and IV-IgGRT are used to prevent
infections in patients with PID and are proven to be safe (79).
The choice of therapy is mainly based on the clinical condition
of the patient, side effects and patient’s preference, as SC-
IgGRT therapy can be administered by the patient at home
independent of help from health care professionals. However, as
mentioned above, the current IgGRT has an important limitation;
it contains only IgG, resulting in the absence or low levels of
IgA and/or IgM in patients with PID. Despite IgGRT, many
patients with PID develop chronic lung disease (57, 59, 66).
Therefore, improvements in therapy are needed, which might be
the addition of IgA and/or IgM.
There are a limited number of IgA- and/or IgM-enriched
immunoglobulin preparations used in clinical practice. Here, we
summarize studies that have used IgA- and/or IgM-enriched
immunoglobulin products, mainly in treatment of acute bacterial
infections in general and highlight the studies focused on
infections in immunoglobulin deficient patients.
Fresh Frozen Plasma
Fresh frozen plasma (FFP) was advocated over IM-IgGRT by
Richard Stiehm in 1975 (80) and was next to IM-IgGRT used in
the early days (81). The IgG levels achieved with FFP treatment
were significantly higher as compared to IM-IgGRT, while IgM
and IgA levels were only slightly increased (80). The use of FFP
has limited or no side effects, but to reach a normal level of
IgA and IgM, it should be given at a high frequency (∼ twice a
week), which is inconvenient for the patient. FFP was also given
to PID patients with chronic gastro-intestinal infections as add-
on therapy to their normal IgGRT. Two patients with relapsing
Campylobacter jejuni infection were given FFP for 2 or 4 weeks
(500mL twice weekly), which resulted in complete recovery of
both patients (82). Plasma infusion resulted in detectable serum
IgA levels in two patients and detectable serum IgM levels in 1
patients (82). Although we have not found direct evidence, FFP
might be beneficial as an treatment, next to normal IgGRT, to
eliminate chronic bacterial respiratory tract infections.
Pentaglobin
Pentaglobin is an IgA- and IgM-containing immunoglobulin
preparation collected from Cohn fraction III, consisting of
72% IgG, 12% IgM, and 16% IgA for intravenous use (83).
Pentaglobin is treated with ß-propiolactone, which decreases
immunoglobulin aggregation, but also affects complement
fixation and Fc-binding capacity (84, 85). A clear beneficial
effect of Pentoglobin in comparison to conventional intravenous
IgG is its effective reduction of endotoxin (86, 87). Direct
effects on bacterial killing has also been observed by in vitro
experiments. For instance, Pentaglobin had a greater opsonic
activity against Pseudomonas aeruginosa, Staphylococcus aureus
and Escherichia coli, in comparison to IV-IgGRT (88, 89). In
a S. aureus mouse sepsis model, the number of bacteria in
liver and kidney were significantly lower for animals receiving
Pentaglobin in comparison to animals receiving IV-IgGRT
Intratect (89). Pentaglobin has to our knowledge not been used
as replacement for conventional IgGRT, but, it has successfully
been applied to treat two hypogammaglobulinemia patients with
persistent gastroenteric C. jejuni infections (90). In these two
patients, six dosages of Pentaglobin at 3-week intervals were
well tolerated (90). After the first dose, an increased serum
bactericidal antibody activity against C. jejuni was measured
and treatment resulted in the elimination of the C. jejuni
infections (90). This result is in line with the use of IgA- and
IgM-containing FFP, which was also successfully used to treat
chronic C. jejuni infections (82). We have found a remarkable
increase in complement-mediated killing of C. jejuni (31) by
supplementing purified serum IgM to serum of a patients with
agammaglobulinemia, supporting an important role for IgM in
complement-mediated protection against bacterial pathogens.
Trimodulin
Trimodulin (BT-588, predecessor BT-086) contains twice
the amount of IgA (21%) and IgM (23%) in comparison to
Pentaglobin. Trimodulin is not treated with ß-propiolactone
and showed approximately 10-fold increase in opsonization
of E. coli compared to Pentaglobin (91). In a rabbit model for
endotoxemia, Trimodulin showed an increased elimination of
E. coli from the bloodstream (92). Recently, the results of a phase
II trial, which included 160 patients with severe community-
acquired pneumonia, were published (93). Although no
difference was observed for ventilator-free days between the
placebo and Trimodulin groups, post-hoc analyses supported
improved outcome in patients with elevated CRP, reduced IgM,
or both. In addition, Trimodulin seemed to prevent secondary
bacterial infections because infection-related treatment-
emergent adverse events were significantly decreased from 57%
in the placebo group to 33% in the Trimodulin-treated patients
(93). Since IgA and IgM concentrations present in Trimodulin
are higher compared to Pentaglobin, we would expect an additive
effect on preventing bacterial infections of the respiratory tract,
although this has not been determined to date.
IgAbulin
IgAbulin is an IgA-enriched IgG preparation, which was shown
to prevent necrotizing enterocolitis when administered orally to
babies with low birth weight (94) and has successfully been used
to treat children with chronic diarrhea (95). Oral administration
of IgAbulin daily for 3 weeks decreased the number of stools
per day and improved the consistency of the stools (95). So
far, IgA-enriched IgGRT has not been used to prevent or
treat bacterial respiratory tract infections. Since IgA is the
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most abundant immunoglobulin isotype on the respiratory tract
mucosal surface, with divers functions in preventing bacterial
infections, it might help in preventing and clearing bacterial
infections. A possible limitation of the current IgA-enriched
immunoglobulin preparations is that they are isolated from
plasma, and plasma-derived IgA is mainly IgA1, which is more
sensitive to bacterial IgA proteases (96), in comparison to IgA2,
which is most abundant on the mucosal surface (16). In addition,
the majority of serum-derived IgA is monomeric (17), in contrast
to locally produced IgA, which is mainly dimeric (16). But,
administration of sufficient IgA might potentially be effective in
preventing bacterial respiratory tract infections, especially in PID
patients with concurrent IgA deficiency.
Purified Serum IgA and IgM Linked to
Recombinant Secretory Component
Although not in clinical trials, plasma-derived IgA and IgM
containing recombinant secretory component have been tested
in animal studies with promising results. It has been shown that
plasma-derived IgA and IgM can bind recombinant secretory
component to form sIgA and sIgM (97). Addition of the secretory
component increased resistance to protease activity and showed
to prevent Shigella flexneri-induced intestine epithelial cell
damage in an in vitro cell model (98). sIgA and sIgM preparations
were found to bind and agglutinate Salmonella enterica
Typhimurium (99). Oral administration of sIgA and sIgM
preparations effectively limited S. Typhimurium infection and
systemic dissemination in mice (99). No results were published
regarding the effects on protection of bacterial respiratory
pathogens, but since these sIgA and sIgM preparations are able
to block bacterial adhesion, it is expected to prevent acquisition
of bacteria in the respiratory tract when applied to the airways.
In addition, these sIgA and sIgM preparations are not treated
with ß-propiolactone, preserving natural complement fixating
activity. Future experiments are required to address the efficacy
to prevent bacterial respiratory tract infections.
CONCLUDING REMARKS
Current IgGRT treatment has not shown to prevent bacterial
respiratory tract infections in a selection of PID patients. Based
on the clinical presentation of patients with IgA and IgM
deficiencies, whomainly present with respiratory tract infections,
it is conceivable that IgA- and/or IgM-enriched immunoglobulin
replacement therapy with biologically active IgA and/or IgM
have the potential to prevent these type of infections. In the
near future, pre-clinical in vitro assays, animal experiments
and clinical trials have to be conducted to determine whether
IgA and/or IgM-enriched immunoglobulin replacement therapy
would prevent bacterial respiratory tract infections in patients
with PID.
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